The Bank of Montreal Can Buys Shares of 5,254 Puma Biotechnology Inc (PBYI)

The Bank of Montreal Can Buys Shares of 5,254 Puma Biotechnology Inc (PBYI)

A number of other hedge funds have also bought and sold shares of the stock. Perceptive Advisors LLC acquired a new stake in Puma Biotechnology during the fourth quarter worth $225,000. Traynor Capital Management Inc. boosted its stake in shares of Puma Biotechnology by 27.1% in the third quarter. Traynor Capital Management Inc. now owns 10,972 shares of the biopharmaceutical company’s stock valued at $468,000 after buying an additional 2,341 shares in the last quarter. Paulson & CO. Inc. purchased a new stake in shares of Puma Biotechnology during the fourth quarter valued at $482,000. Trexquant Investment LP boosted its stake in shares of Puma Biotechnology by 17.6% in the fourth quarter. Trexquant Investment LP now owns 19,326 shares of the biopharmaceutical company’s stock valued at $593,000 after buying an additional 2,897 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY boosted its stake in shares of Puma Biotechnology by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 20,142 shares of the biopharmaceutical company’s stock valued at $618,000 after buying an additional 2,247 shares in the last quarter. 80.98% of the stock is currently owned by institutional investors and hedge funds.

Bank of Montreal Can bought a new position in shares of Puma Biotechnology Inc (NYSE:PBYI) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,254 shares of the biopharmaceutical company’s stock, valued at approximately $195,000.

Shares of Puma Biotechnology Inc (PBYI) opened at 81.95 on Monday. The firm’s 50-day moving average is $45.76 and its 200 day moving average is $39.21. The company’s market capitalization is $3.03 billion. Puma Biotechnology Inc has a 52 week low of $27.64 and a 52 week high of $84.40.

Puma Biotechnology (NYSE:PBYI) last announced its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.06) by $0.09. On average, analysts anticipate that Puma Biotechnology Inc will post ($8.47) earnings per share for the current fiscal year.

PBYI has been the topic of several research analyst reports. Royal Bank of Canada decreased their price objective on shares of Puma Biotechnology from $48.00 to $17.00 and set a “sector perform” rating on the stock in a research note on Thursday, March 2nd. Citigroup Inc reaffirmed a “buy” rating and set a $88.00 price objective on shares of Puma Biotechnology in a research note on Saturday, March 4th. Credit Suisse Group AG reaffirmed an “outperform” rating and set a $58.00 price objective on shares of Puma Biotechnology in a research note on Tuesday, April 18th. Stifel Nicolaus reaffirmed a “buy” rating and set a $88.00 price objective on shares of Puma Biotechnology in a research note on Wednesday, April 19th. Finally, Zacks Investment Research raised shares of Puma Biotechnology from a “hold” rating to a “buy” rating and set a $36.00 price objective on the stock in a research note on Tuesday, May 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $78.61.

In related news, major shareholder Adage Capital Partners Gp, L.L sold 1,235,700 shares of Puma Biotechnology stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $75.38, for a total transaction of $93,147,066.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 22.70% of the company’s stock. About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “PBYI”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology Inc (NYSE:PBYI). Receive News & Ratings for Puma Biotechnology Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Puma Biotechnology Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology Inc (NYSE:PBYI).

Related posts

Leave a Comment